MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue GuidanceGlobeNewsWire • 11/08/23
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue GuidanceGlobeNewsWire • 10/04/23
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingGlobeNewsWire • 09/06/23
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 GuidanceGlobeNewsWire • 08/09/23
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for PatientsGlobeNewsWire • 08/01/23
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular TherapiesGlobeNewsWire • 07/10/23
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 GuidanceGlobeNewsWire • 05/10/23
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell PlatformGlobeNewsWire • 05/04/23